1 Min Read
Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that Vyloy (zolbetuximab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, has been accepted by the Scottish Medicines Consortium (SMC) as a first-line treatment for adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction […] The post Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer appeared first on Pharmafile.
Work & Theory on February 6, 2026
Uncategorized